Novo Nordisk was briefly the most valuable company in Europe. Then it wasn’t. That 50%+ drawdown from its 2024 peak — while Ozempic is still selling at a pace that would make most pharmaceutical companies weep with envy — is the kind of thing that deserves an honest look, not another hot take.
So that’s what this is. Real figures. Real context. No price targets, no “buy the dip” cheerleading. Just what’s actually happening with this company and why people outside of Wall Street should care about it.
The Ozempic Numbers People Keep Getting Wrong
Novo Nordisk’s full-year 2024 results showed total net sales of DKK 232.3 billion — roughly $33.7 billion USD — up 25% year-over-year. That’s not a typo. Source: Novo Nordisk Annual Report 2024.
The GLP-1 segment — which covers semaglutide products including Ozempic (diabetes) and Wegovy (obesity) — drove the bulk of that. Wegovy alone pulled in DKK 46.8 billion in 2024, a 76% jump from 2023. Ozempic added DKK 85.6 billion. Combined, those two drugs account for roughly 57% of total company revenue.
That concentration is both the strength and the risk. And it’s the thing most surface-level coverage glosses over.
[IMAGE: Novo Nordisk Ozempic Wegovy semaglutide injection pen 2024 | CAPTION: Two drugs. 57% of all Novo Nordisk revenue. The dependency question is the one most headlines skip.]
What Actually Happened to the Stock Price
NVO hit an all-time high around $148 per share in June 2024. By early 2025, it had dropped to the mid-$60s. As of May 2026, it’s been trading in a range that reflects genuine uncertainty — not panic, not euphoria. Just the market trying to price in a legitimately complicated situation.
The catalyst for the collapse? CagriSema trial data. In December 2024, Novo’s combination drug — cagrilintide plus semaglutide — showed 22.7% weight loss in its REDEFINE 1 trial. Analysts had been expecting closer to 25%. The market had priced in perfection. It didn’t get perfection. The stock dropped roughly 20% in a single day. Novo Nordisk press release, December 20, 2024.
22.7% weight loss is, by any objective measure, an extraordinary clinical result. The fact that it disappointed markets tells you more about how the stock was priced than about the drug itself.
People in r/personalfinance and r/investing on Reddit had a field day with this. One thread titled “NVO down 20% on ‘disappointing’ 22% weight loss results — the market is broken” got thousands of upvotes, with the top comment being: “The drug works incredibly well. The stock was just priced for miracles.” That’s actually a pretty clean summary.
The Competition That’s Eating Into Novo’s Lead
Eli Lilly. That’s the name Novo Nordisk has to say out loud every morning.
Tirzepatide — sold as Mounjaro for diabetes and Zepbound for obesity — has been consistently outperforming semaglutide in head-to-head weight loss comparisons. The SURMOUNT-5 trial, published in January 2025 in The New England Journal of Medicine, showed tirzepatide users lost 47% more weight than semaglutide users over 72 weeks. NEJM, January 2025.
Lilly’s US market share in the GLP-1 obesity space has been growing. Novo still leads on global volume — particularly in Europe, where Wegovy has stronger formulary coverage — but the US narrative has shifted. Lilly is winning the headlines.
And then there’s the oral semaglutide question. Novo’s Rybelsus already exists as an oral GLP-1, but it underperforms the injectable version on efficacy. The next-generation oral semaglutide (higher dose formulation) is in trials. If that works at injectable-comparable levels, it changes the access equation significantly — oral pills are easier to prescribe, easier to take, and potentially easier to manufacture at scale.
Manufacturing: The Bottleneck Nobody Talks About Enough
For most of 2023 and into 2024, Wegovy was supply-constrained. Not because demand was soft — the opposite. Novo simply couldn’t make enough of it fast enough. The company has been pouring capital into manufacturing expansion: $6.1 billion committed to US manufacturing capacity expansion announced in 2024, including a major facility in Clayton, North Carolina. Novo Nordisk US press release, June 2024.
That capital expenditure is necessary. It’s also a bet on sustained demand over a 5-10 year horizon. If a competing drug — oral or otherwise — significantly undercuts semaglutide before those factories are fully operational, that’s a stranded asset problem.
This is the kind of thing that doesn’t make it into the “Ozempic is changing the world” headlines. But it’s real.
[IMAGE: pharmaceutical manufacturing facility injectable drug production line 2025 | CAPTION: Novo Nordisk committed $6.1B to US manufacturing — a bet on demand that still has to play out over the next decade.]
A Quick Look at the Numbers Side-by-Side
| Metric | 2023 | 2024 | Change |
|---|---|---|---|
| Total Net Sales (DKK bn) | 232.3* | 232.3 | — |
| Total Net Sales (DKK bn) | 185.4 | 232.3 | +25% |
| Wegovy Revenue (DKK bn) | 26.6 | 46.8 | +76% |
| Ozempic Revenue (DKK bn) | 58.7 | 85.6 | +46% |
| Operating Profit Margin | 44.1% | 45.1% | +1pp |
| R&D Spend (DKK bn) | 27.5 | 34.1 | +24% |
Source: Novo Nordisk Annual Report 2024. All figures in Danish Krone (DKK). 1 USD ≈ 6.9 DKK as of May 2026.
The margin staying above 45% while R&D spending grew 24% is notable. They’re investing heavily and still printing money. That’s a genuinely strong operational profile — which is why the stock story is complicated rather than simple.
The Patent Cliff and What It Means for Patients
Here’s where it gets interesting for people who aren’t tracking NVO as a ticker but are tracking it as a medication they or someone they know might need.
Semaglutide’s core composition-of-matter patents expire in the early 2030s in the US. After that, generic manufacturers can produce biosimilar versions. The FDA’s biosimilar pathway for complex molecules like semaglutide is more demanding than for small-molecule drugs, so we’re not talking about overnight generic competition. But it’s coming.
When it does? The price of GLP-1 drugs — currently around $1,000/month for Wegovy in the US without insurance — could drop dramatically. A 2023 analysis published in JAMA Internal Medicine estimated that a competitive biosimilar market could reduce semaglutide costs to as low as $100/month. JAMA Internal Medicine, 2023.
For the roughly 70% of Americans who currently can’t access Wegovy due to cost or coverage gaps — that’s an enormous shift. The drug’s clinical efficacy is not in question. Access is the bottleneck. The patent cliff, from a public health standpoint, is actually good news for patients.
Novo Nordisk knows this. Their strategy is to stay ahead of the biosimilar wave with next-generation compounds — oral formulations, combination drugs, cardiovascular indications — so that by the time semaglutide biosimilars arrive, they’ve already moved the market to something newer.
The Cardiovascular Data That Changed the Conversation
The SELECT trial, published in The New England Journal of Medicine in late 2023, showed that semaglutide reduced major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with obesity but without diabetes. NEJM, November 2023.
That’s not a weight loss story anymore. That’s a cardiovascular drug story. And cardiovascular drugs — statins, for example — have much broader prescribing patterns and insurance coverage than obesity medications, which have historically been treated as “lifestyle” drugs by payers.
The FDA approved Wegovy for cardiovascular risk reduction in March 2024. That approval matters enormously for reimbursement. Medicare and major insurers started revisiting coverage decisions. If Wegovy gets treated more like a statin and less like a diet pill, the addressable patient population expands by tens of millions.
Hacker News had a thread on this that’s worth reading. The top comment, from a user who identified as a cardiologist: “This is the first time in my career I’ve seen an obesity drug get a CV indication. The clinical community is taking this seriously in a way we haven’t taken obesity drugs before.”
What People Are Getting Wrong About the “Ozempic Shortage”
The FDA’s drug shortage list for semaglutide injection has been a rolling story since 2022. As of mid-2025, the FDA officially declared the shortage resolved for certain doses of Ozempic and Wegovy — but compounding pharmacies, which had been producing semaglutide copies legally during the shortage period, were required to stop.
This created a secondary story: millions of patients who’d been using compounded semaglutide (often cheaper, sometimes of variable quality) suddenly lost access. The FDA’s position is that branded semaglutide is now available at adequate supply levels. Patient advocates pushed back, arguing that “available” and “affordable” are not the same thing.
They’re right. And this is the tension that isn’t going away regardless of what the stock does.
Pik’s Take 🎯
1. The stock decline doesn’t reflect the drug’s performance — it reflects how it was priced. Novo Nordisk’s underlying business is still growing fast. The share price correction is a valuation story, not a fundamentals collapse. These are different things, and conflating them leads to bad analysis.
2. The real story isn’t Novo vs. Lilly. It’s access. Both drugs work. Both companies are making enormous amounts of money. The actual unresolved question is whether the healthcare system — particularly in the US — will ever price these drugs so that the people who need them most can actually get them. The clinical data is settled. The policy and economics are not.
3. Watch the oral semaglutide data closely. If next-generation oral semaglutide hits injectable-comparable efficacy numbers, it changes the entire logistics of GLP-1 therapy. No cold chain. No injection training. Potentially much wider prescribing. That’s the pipeline bet that matters most in the next 18 months — not CagriSema, not the Lilly comparison, not the stock price.
What You Actually Do With This Information
If you’re a patient or have a family member on GLP-1 therapy: the supply situation has improved, but cost remains a real barrier for the uninsured or underinsured. The compounding pharmacy window is closing. If you were using compounded semaglutide, talk to your doctor now about transitioning options or patient assistance programs — Novo Nordisk’s NovoCare program exists and is underused.
If you’re a healthcare professional: the cardiovascular indication is the thing that’s shifting prescribing behavior. The coverage landscape is moving, slowly, in the direction of treating these as maintenance medications rather than optional lifestyle interventions.
If you’re just trying to understand why this company is in the news constantly: the short version is that Novo Nordisk accidentally created one of the most consequential drug classes in modern medicine, got overwhelmed by its own success, and is now navigating the gap between clinical triumph and operational reality. That gap is what 2026 is about.
The numbers are real. The drug works. The access problem is real too. Everything else is noise.
📱 Get Pik’s daily briefings on Telegram → t.me/pikinfo
🔗 Found this useful? Share it with a Piker → pikinfo.com/nvo-stock-reality-real-data-2026
This article is for informational purposes only. Data and projections reflect available information at time of writing. Any price or market forecasts are speculative and should not be taken as financial advice.